Background - PrEP and STIs

- Pre-exposure prophylaxis (**PrEP**) is highly effective in preventing HIV, **but no protection against other sexually transmitted infections** (STIs)

- **Rates of STIs are rising** worldwide, with notably high incidences among MSM PrEP-user in high-income countries

- The potential increase risk of STIs during PrEP is though counterbalanced by the <u>increased STIs screening</u> during a regular PrEP visits schedule

- **Antimicrobial Resistance** (AMR) of ***N. gonorrhoeae*** has increased rapidly

MF Lucente ICAR 2023

Few data are available on the **temporal trends of diagnosis and incidence of STIs** in recent years following **PrEP** implementation **in Italy specifically in the city of Milan** among this high-risk group

Aims

Describe among PrEP users of Milano Checkpoint (MCP) in the last 4 years (2019-2022):

1. HIV and HCV incidence

2. Trends of bacterial STIs (chlamydia, gonorrhoea, syphilis) prevalence and incidence

3. Identify groups at higher risk of increased STIs incidence

Milano Checkpoint

- Community-based association in Milan
- Founded by 5 association (ANLAIDS, Arcigay, ASA, LILA, NPS) involved in advocacy for PLWH
- Self-funded
- Started in 2019
- Main Activities:
  - Counseling of rapd tests for HIV and syphilis
  - PrEP service
  - Infopoint (*Mi'mportavenezia*) in the LGBTQ district of Milan for promoting health and harm reduction intervention on drugs and alcohol

AMSTE DAM
FAST-TRACK CITIES 2023

Methods

- Retrospective analysis of prospectively collected data of **PrEP users** attending the community-based service of **Milano Check Point from 2019 to 2022**

- Demographic and clinical information together with sexual and behavioural features were collected though an **online self-administered questionnaire before every PrEP visit**

- Follow-up visits every **4 months**

- During each visit PrEP users undergo screening for **HIV**, **HCV** and **syphilis** (Lue) with **Point-of-Care Test** (POCT) and screening for *Chlamydia trachomatis* (Ct), *Neisseria gonorrhoea* (Ng), using the rapid GeneXpert platform with Xpert CT/NG **NAAT assays** (Cepheid) on pooled samples from urine, anal and pharyngeal sites.

Statistical analysis

- PrEP users were **included** if they **had least one STI test**

- Prevalence and incidence rates (IR) of **HCV and HIV seroconversions** has been calculated

- **Repeated tests** after 1st visit were counted to calculate chlamydia, gonorrhoea and syphilis **IR over years.**

- Each user can participate to IR calculation of different calendar year according to individual's FU

- **Incidence rate ratios** (IRRs) used to estimate changes in **STIs incidence per calendar year** were calculated using **Poisson regression model**, crude and adjusted for age and nation of birth (Italian born vs non-native).

- **Differences** in IR and IRR over calendar years have been further calculated **according to nation of birth and age strata**

Study Population
PrEP users of MCP (N=878)

MCP PrEP users in FU/year

PrEP users MCP (N=878)		
Age, median (IQR)	36	31-44
<25	50	5.7%
25-39	499	56.8% ←
>39	329	37.5%
Gender		
M	858	97.7% ←
F	12	1.4%
TGW	8	0.9%
Sexual Orientation		
Hetero	29	3.3%
MSM	846	96.6% ←
Bisex	*94*	*10.7%*
Nation of Birth, ITA	696	79.3%
Relationship Status		
Partner	229	26.1%
Single	645	73.5%
Unknown	4	0.4%
Education, University	602	68.6% ←
Job, Employed	753	86.1% ←
Sex workers	30	3.4% ←
Previous STIs (1st visit)	252	29.1%
Chemsex use (1st visit)	139	16.0% ←
Slam (1st visit)	8	0.9% ←
5PDi use (1st visit)	147	17.0%
Sex under alcohol (1st visit)	441	51.2%
Fisting/Sex Toys sharing/ Group sex (1st visit)	324	37.4% ←

HIV seroconversions

HCV seroconversions

1 HIV seroconversion (0.11%)

4 HCV seroconversions (0.45%)

0.99 x 1000 PYFU (95CI% 0.02-5.56)

4.00 x 1000 PYFU (95%CI 1.09-10.24)

- *User on 'On demand' PrEP schedule for 1.3 years*
- *PrEP not interrupted but not taken it correctly*
- *Last negative HIV test 2.9 months*
- *CD4 count 929 cells/mmc*
- *HIV-RNA 841 copis/ml*
- *M184V*

No HCV-reinfections (till Dec2022)

AMSTERDAM
FAST-TRACK CITIES 2023

Syphilis infections – prevalence and incidence /year

83 syphilis positive test in 73 PrEP users:

(9.4%; 95%CI 7.6-11.6)

| year	Lue pos	PrEP users tested	prevalence Lue (95%CI)	Incident Lue pos test	PYFU	Incidence Rate Lue (x100 PYFU)
2019	7	133	5.3% (2.1-10.5)	3	65.6	4.6 (0.9-13.4)
2020	10	265	3.8% (1.8-6.8)	9	143.8	6.3 (2.9-11.9)
2021	33	518	6.4% (4.4-8.8)	20	330.0	6.1 (3.7-9.4)
2022	33	683	4.8% (3.3-6.7)	29	377.6	7.7 (5.1-11)
Total	83			61	917.0	6.7 (5.1-8.5)

| Lue	IRR	95%CI		p	aIRR*	95%CI		p
2019	1.00				1.00			
2020	1.37	0.37	5.05	0.638	1.39	0.38	5.14	0.620
2021	1.32	0.39	4.46	0.65	1.36	0.40	4.58	0.620
2022	1.68	0.51	5.51	0.393	1.72	0.52	5.64	0.374

*IRR and aIRR of Syphils infection, by fitting Poisson regression model (*Adjusted for age and nation of birth)*

Chlamydia infections – prevalence and incidence / year

329 Ct positive test in 234 PrEP users:

(26.6%; 95%CI 23.7-29.7)

year	Ct pos	users tested	prevalence Ct (95%CI)	Incident Ct pos test	PYFU	Incidence Rate Ct x100 PYFU (95%CI)
2019	30	158	19.0% (13.2-26)	20	80.5	24.8 (15.2-38.4)
2020	31	276	11.2% (7.8-15.6)	24	151.0	15.9 (10.2-23.6)
2021	117	515	22.7% (19.2-26.6)	84	325.1	25.8 (20.6-32)
2022	151	685	22.0% (19-25.3)	125	377.8	33.1 (27.5-39.4)
Total	329			253	934.3	27.0 (23.8-30.6)

| Ct	IRR	95%CI		p	aIRR*	95%CI		p
2019	1.00				1.00			
2020	0.64	0.35	1.16	0.141	0.64	0.35	1.16	0.139
2021	1.04	0.64	1.69	0.873	1.04	0.64	1.69	0.883
2022	1.33	0.83	2.14	0.233	1.32	0.82	2.11	0.254

*IRR and aIRR of Ct infection, by fitting a Poisson regression model (*Adjusted for age and nation of birth)*

AMSTERDAM
FAST-TRACK CITIES 2023

Gonorrhea infections – prevalence and incidence/year

318 Ng positive test in 227 PrEP users:

(25.8%; 95%CI 23.0-28.9)

| year	Ng pos	users tested	prevalence Ng (95%)	Incident Ng pos test	PYFU	Incidence Rate Ng x100 PYFU (95%CI)
2019	22	158	13.9% (9-17.2)	14	80.5	17.4 (9.5-29.2)
2020	35	278	12.7% (17.7-25)	19	151.0	12.6 (7.6-19.6)
2021	109	515	21.2% (19.1-25.5)	76	325.1	23.4 (18.4-29.3)
2022	152	685	22.2% (17.5-21.4)	130	377.6	34.4 (28.8-40.9)
Total	318			239	934.3	25.5 (22.4-29)

Ng	IRR	95%CI		p	aIRR*	95%CI		p
2019	1.00				1.00			
2020	0.72	0.36	1.44	0.36	0.72	0.36	1.44	0.354
2021	1.34	0.76	2.38	0.308	1.34	0.76	2.36	0.32
2022	1.98	1.14	3.44	**0.015**	1.95	1.12	3.39	**0.018**

IRR and aIRR of Ng infection, by fitting Poisson regression model
*Adjusted for age and nation of birth*

AMSTERDAM
FAST-TRACK CITIES 2023

Gonorrhea IR by age and nation of birth

by nation of birth

*p-value for interaction year*ita < 0.001*

	Italian native			non-italian native		
	aIRR	95CI%	p	aIRR	95CI%	p
2019-2020	1			1		
2021	1.56	1.00-2.43	0.047	2.50	0.83-7.52	0.104
2022	**2.20**	1.45-3.33	<.001	**4.16**	1.47-11.74	0.007

by age strata

*p-value for interaction year*age_strata < 0.001*

	<30 yrs			>=30 yrs		
	aIRR	95CI%	p	aIRR	95CI%	p
2019-2020	1			1		
2021	2.00	0.76-5.26	0.162	1.58	1.00-2.48	0.046
2022	**4.04**	1.68-9.74	0.002	**2.16**	1.41-3.31	<.001

Limitations

- MCP is a self-funded institution → no other STIs tested

- No info on **antibiotic resistance** of positive samples

- Effect of **MenB** vaccine still under investigation

- No info on **Doxy-PEP** use for MCP users

- Analysis don't include **STIs – between visits** -outside MCP

- **Pooling** of anal, pharyngeal and urine samples **could reduce sensitivities** for low Ng/Ct bacterial loads

Underestimation STIs incidence

AMSTERDAM
FAST-TRACK CITIES 2023

Conclusions

- PrEP is **effective as prevention** strategy with only 1 serconversions in 4 years in this high risk group

- **Low** circulation of **HCV in Italy** among MSM → 'slam' practicing not widespread in Italy

- **Chlamydia and Gonorrhea incidences** among PrEP users were **high** (>25 x 100PYFU) but comparable with literature data on PrEP users from HIC

- **Syphilis** incidence remains **low** throughout the follow-up period

- In **2022 a significant increase in Ng** has been identified with an incidence **2-times** higher compared to 2019, more relevant among **non-Italians** and **younger** PrEP users (4-times higher)

- Monitoring both the sexual behaviours/compensation and the actual diagnosis of STIs for PrEP users is an essential role PrEP services for controlling the burden of STIs

- Particularly important during the Ng "outbreak", given the high contagiousness and the reports of resistance

Acknowledgments

<u>Milano Checkpoint Team</u>

Antonella Antonino, Abu Baby, Alessandra Bianchi, Lorenzo Biasioli, Simona Bossolasco, Elena Bruzzesi, Daniele Calzavara, Diana Canetti, Enrico Caruso, Massimo GL Cernuschi, Anna De Bona, Dominic De Cia, Claudio Ferrara, Vittorio Ferrara, Antonella Foschi, Nicoletta Frattini, Emilio Garavaglia, Giuseppe Lapadula, Monica Massa, Davide Moschese, Camilla Muccini, Giovanni Mulé, Roberto Repossi, Federica Rossi, Alessandro Soria, Elisa Suardi, Alessandro Tavelli, Daniele Tesoro, Paolo Testoni, Pietro Vinti, Antonella d'Arminio Monforte